Edwards Lifesciences Corp

Edwards Lifesciences Corp

EW

Get informed when a big investor buys or sells

+ Follow
Market Cap$49.79B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Edwards Lifesciences CorpEdwards Lifesciences Corp45.8-11%8.60.1

Earnings Call Q4 2025

February 10, 2026 - AI Summary

Strong Performance in Q4 and Full Year 2025: Edwards Lifesciences reported Q4 sales of $1.57 billion, growing 11.6% year-over-year, with full-year growth at 10.7%. TAVR sales specifically reached $1.16 billion, reflecting a robust 10.6% growth from the previous year. The strength in performance is attributed to solid execution of their strategic focus on Structural Heart.
Guidance for 2026: The company has increased its confidence in meeting its full-year 2026 sales growth guidance of 8% to 10% and adjusted EPS guidance of $2.90 to $3.05. Q1 sales are projected between $1.55 billion and $1.63 billion, indicating a continued positive growth trajectory.
Investment in Patient Access Initiatives: A significant rise in SG&A spending (up $112 million year-over-year) reflects the company's strategy to amplify patient access, driven by initiatives such as early TAVR education and reinforcements in their field force. While this spending is expected to moderate in 2026, it raises questions about efficiency and profitability in the short term.

Exclusive for Stockcircle Pro members

Sign upSign Up
$95.10

Target Price by Analysts

10.6% upsideEdwards Lifesciences Target Price DetailsTarget Price
$47.30

Current Fair Value

45% downside

Overvalued by 45% based on the discounted cash flow analysis.

Share Statistics

Market cap$49.79 Billion
Enterprise Value$48.09 Billion
Dividend Yield$- (-)
Earnings per Share$1.84
Beta0.87
Outstanding Shares579,200,000

Return

Return on Equity10.61%ROE
Return on Assets8.23%
Return on Invested Capital11.02%

Valuation & Multiples

P/E Ratio45.83P/E Ratio
PEG722.79PEG
Price to Sales8.6Price to Sales
Price to Book Ratio5.06Price to Book Ratio
Enterprise Value to Revenue7.63
Enterprise Value to EBIT36.65
Enterprise Value to Net Income43
Total Debt to Enterprise0.01
Debt to Equity0.07Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 23, 2026
EPS Estimate
$0.73
Average shareholder expectation
Revenue Estimate
$1.60 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 23, 2026
EPS Estimate
$0.74
Average shareholder expectation
Revenue Estimate
$1.70 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio1.5154 18.28%
Total Calls1,543,982 49.50%
Total Puts2,339,797 42.58%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %86.11% 0.27%
Total Invested$40.32B 6.37%
Investors Holding1,330 33.00%

ESG Score

No data

About Edwards Lifesciences Corp

CEO: Michael Mussallem

Relevant Senate Committees

Finance

This powerful committee controls taxation, trade, and entitlement spending, including Medicare and Medicaid. Its decisions on tax policy and healthcare reimbursement rates (e.g., for heart valves and surgical instruments) directly impact Edwards Lifesciences' profitability and market access.

Appropriations

This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for various healthcare programs (e.g., Medicare, NIH research, VA hospitals), directly impacting the demand for and reimbursement of Edwards Lifesciences' medical devices.

Health, Education, Labor, and Pensions

This is a primary committee for the medical device industry, as it regulates the FDA (Food and Drug Administration) and NIH (National Institutes of Health). FDA oversight is central to product approval, manufacturing, and marketing for Edwards Lifesciences.

Judiciary

This committee oversees antitrust laws and intellectual property. Intellectual property protection (patents) is critical for medical device innovation and competitiveness, making this committee highly relevant to Edwards Lifesciences' core assets.

Veterans' Affairs

This committee directly oversees the Department of Veterans Affairs. Its funding and policy decisions directly impact government healthcare contractors and medical device manufacturers like Edwards Lifesciences, especially if they supply VA hospitals and clinics.